112 related articles for article (PubMed ID: 11985351)
1. Influence of thalidomide on Bcl2 expression and proangiogenic cytokine levels in short-term culture of peripheral blood and bone marrow mononuclear cells of multiple myeloma patients.
Dmoszyńska A; Roliński J; Bojarska-Junak A; Mańko J; Jawniak D; Walter-Croneck A; Soroka-Wojtaszko M; Hus M
Pol J Pharmacol; 2001; 53(6):709-13. PubMed ID: 11985351
[TBL] [Abstract][Full Text] [Related]
2. The influence of thalidomide therapy on cytokine secretion, immunophenotype, BCL-2 expression and microvessel density in patients with resistant or relapsed multiple myeloma.
Dmoszynska A; Podhorecka M; Manko J; Bojarska-Junak A; Rolinski J; Skomra D
Neoplasma; 2005; 52(2):175-81. PubMed ID: 15800717
[TBL] [Abstract][Full Text] [Related]
3. [Influence of thalidomide on bone marrow microenvironment in refractory and relapsed multiple myeloma].
Li J; Luo SK; Hong WD; Zhou ZH; Zou WY
Ai Zheng; 2003 Apr; 22(4):346-9. PubMed ID: 12703985
[TBL] [Abstract][Full Text] [Related]
4. [Influence of thalidomide on interleukin-6 and its transmission in multiple myeloma patients].
Li J; Luo S; Hong W; Zhou Z; Zou W
Zhonghua Zhong Liu Za Zhi; 2002 May; 24(3):254-6. PubMed ID: 12515619
[TBL] [Abstract][Full Text] [Related]
5. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
6. Soluble IL-6R alpha upregulated IL-6, MMP-1 and MMP-2 secretion in bone marrow stromal cells.
Barillé S; Collette M; Thabard W; Bleunven C; Bataille R; Amiot M
Cytokine; 2000 Sep; 12(9):1426-9. PubMed ID: 10976008
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma.
Vacca A; Scavelli C; Montefusco V; Di Pietro G; Neri A; Mattioli M; Bicciato S; Nico B; Ribatti D; Dammacco F; Corradini P
J Clin Oncol; 2005 Aug; 23(23):5334-46. PubMed ID: 15939924
[TBL] [Abstract][Full Text] [Related]
8. [Production of interleukin-1 and interleukin-6 in a culture of mononuclear cells of peripheral blood and bone marrow in multiple myeloma].
Kliushnenkova EN; Lutskaia TD; Golenkov AK; Malaĭtsev VV
Biull Eksp Biol Med; 1993 May; 115(5):507-10. PubMed ID: 8043836
[TBL] [Abstract][Full Text] [Related]
9. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
[TBL] [Abstract][Full Text] [Related]
10. [Study of anti-myeloma activity of interleukin-2 activated bone marrow in vitro].
Liu W; Chen SL; Liu JW; Li X; Xia CQ; Qi M
Zhonghua Xue Ye Xue Za Zhi; 2005 Apr; 26(4):205-8. PubMed ID: 15949260
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of idiotype vaccination on the specific T-cell response in peripheral blood and bone marrow of multiple myeloma patients.
Abdalla AO; Hansson L; Eriksson I; Näsman-Glaser B; Mellstedt H; Osterborg A
Eur J Haematol; 2007 Nov; 79(5):371-81. PubMed ID: 17916084
[TBL] [Abstract][Full Text] [Related]
12. Dehydroepiandrosterone can inhibit the proliferation of myeloma cells and the interleukin-6 production of bone marrow mononuclear cells from patients with myeloma.
Liu S; Ishikawa H; Li FJ; Ma Z; Otsuyama K; Asaoku H; Abroun S; Zheng X; Tsuyama N; Obata M; Kawano MM
Cancer Res; 2005 Mar; 65(6):2269-76. PubMed ID: 15781640
[TBL] [Abstract][Full Text] [Related]
13. Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma.
Dmoszyńska A; Bojarska-Junak A; Domański D; Roliński J; Hus M; Soroka-Wojtaszko M
Leuk Lymphoma; 2002 Feb; 43(2):401-6. PubMed ID: 11999576
[TBL] [Abstract][Full Text] [Related]
14. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
[TBL] [Abstract][Full Text] [Related]
15. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.
Heider U; Langelotz C; Jakob C; Zavrski I; Fleissner C; Eucker J; Possinger K; Hofbauer LC; Sezer O
Clin Cancer Res; 2003 Apr; 9(4):1436-40. PubMed ID: 12684416
[TBL] [Abstract][Full Text] [Related]
16. Response to thalidomide in multiple myeloma: impact of angiogenic factors.
Rosiñol L; Cibeira MT; Segarra M; Cid MC; Filella X; Aymerich M; Rozman M; Arenillas L; Esteve J; Bladé J; Montserrat E
Cytokine; 2004 May; 26(4):145-8. PubMed ID: 15149630
[TBL] [Abstract][Full Text] [Related]
17. Role of soluble gp130 in the tumour necrosis factor-alpha expression and its production by peripheral blood mononuclear cells.
Jablonskaca E; Puzewska W; Marcinczyk M; Jablonski J
Mediators Inflamm; 2003 Dec; 12(6):355-9. PubMed ID: 14668095
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the cytokine pattern of porcine bone marrow-derived cells treated with 1alpha,25(OH)D.
Sipos W; Duvigneau JC; Schmoll F; Exel B; Hofbauer G; Baravalle G; Hartl RT; Dobretsberger M; Pietschmann P
J Vet Med A Physiol Pathol Clin Med; 2005 Oct; 52(8):382-7. PubMed ID: 16176565
[TBL] [Abstract][Full Text] [Related]
19. Normal bone marrow hematopoietic stem cell reserves and normal stromal cell function support the use of autologous stem cell transplantation in patients with multiple sclerosis.
Papadaki HA; Tsagournisakis M; Mastorodemos V; Pontikoglou C; Damianaki A; Pyrovolaki K; Stamatopoulos K; Fassas A; Plaitakis A; Eliopoulos GD
Bone Marrow Transplant; 2005 Dec; 36(12):1053-63. PubMed ID: 16205726
[TBL] [Abstract][Full Text] [Related]
20. [Multiple myeloma: the role of angiogenesis and therapeutic application of thalidomide].
Jurczyszyn A; Wolska-Smoleń T; Skotnicki AB
Przegl Lek; 2003; 60(8):542-7. PubMed ID: 14974349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]